외국의 약물유전정보

Propranolol

미국 FDA   원본 보기 | 번역본 보기

12 CLINICAL PHARMACOLOGY

12.3 Pharmacokinetics

Metabolism and Elimination: In healthy subjects, no difference was observed between CYP2D6 extensive metabolizers (EMs) and poor metabolizers (PMs) with respect to oral clearance or elimination half-life. Partial clearance to 4-hydroxy propranolol was significantly higher and to naphthyloxylactic acid was significantly lower in EMs than PMs.